Urge Urinary Incontinence (UUI) Reaches High Levels among Women However These Patients Are Not Presenting the Problem to Their Physicians.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36793) has announced the addition of Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake to their offering.

Urge urinary incontinence (UUI) is a relatively common disorder which can affect all age groups but becomes increasingly prevalent with old age. Although several pharmacological therapies are available for treating this distressing condition, patient's reluctance to present to a physician and incorrect diagnosis of the different overactive bladder subtypes limit the potential of this market.

Scope of this title:

--Quantitative treatment data from 418 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments

--Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for UUI

--Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin

--Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline

Highlights of this title:

Although the prevalence of UUI in women is high, the potential of this market is limited by the reluctance of patients to present to a physician for treatment. Direct to consumer advertising, where available, has already increased awareness and presentation of this condition but other strategies are also required to assist in enlarging the market.

In theory, UUI could be managed successfully by PCPs. However, there is little belief in their ability to correctly diagnose the subtypes of OAB and this lack of confidence is supported by inappropriate prescribing trends by PCPs. Methods to address diagnosis and treatment of UUI in the primary care setting should reflect the priorities of PCPs.

Older treatments for UUI are associated with a number of unpleasant side effects, leaving significant unmet need in this market. Several new products have recently entered the market yet there is little perceived differentiation from existing treatments. Emphasizing the improved efficacy and side effect profiles is key to improving uptake.

Reasons to Read this Report:

--Forecast product sales by understanding key aspects of UUI epidemiology, diagnosis and treatment

--Gain a better understanding of the challenges facing current and future players in the UUI market

--Identify physicians' key concerns in UUI including unmet needs and the attributes that physicians believe are desirable for future treatments

Contents are:

Overview

Appendix A

Appendix B

For more information visit http://www.researchandmarkets.com/reports/c36793

Source: Datamonitor